Acupuncture for Stiffness of Joint Related to Aromatase Inhibitors in Patients With Early-Stage Breast Cancer

NCT ID: NCT05098951

Last Updated: 2021-11-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

52 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-10-20

Study Completion Date

2023-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Acupuncture may help relieve joint stiffness related to aromatase inhibitors in patients with early-stage breast cancer.

PURPOSE: This single arm clinical study aims to evaluate how well acupuncture as a non-pharmacological treatment, works in treating patients with joint stiffness related to aromatase inhibitors (AIs) in patients with early-stage breast cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Objectives of this study:

Primary objective:

To evaluate whether acupuncture as a non-pharmacological treatment, administered twice weekly for 6 weeks can significantly reduce joint stiffness related to AIs in women with early-stage breast cancer as measured by the Western Ontario and McMasters Universities Osteoarthritis (WOMAC) stiffness score at weeks 6.

Secondary objectives:

To evaluate the effect of acupuncture on joint stiffness measured by the WOMAC stiffness score at weeks 12.

To evaluate the effect of acupuncture on joint stiffness measured by the Modified Score for the Assessment of Chronic Rheumatoid Affections of the Hands (M-SACRAH) stiffness score at weeks 6 and weeks 12.

To evaluate the effects of acupuncture on quality of life (QOL) assessed by the Functional Assessment of Cancer Therapy-Endocrine Subscales (FACT-ES) at weeks 6 and weeks 12.

To evaluate the safety and tolerability of acupuncture in the enrolled patients.

To identify potential genetic determinants to response to acupuncture.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Stiffness of Hand, Not Elsewhere Classified

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Breast cancer Stiffness Aromatase inhibitor Acupuncture High altitude

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with stiffness of joint receive acupuncture therapy

This is a single arm study. All the enrolled patients will receive acupuncture twice weekly for 6 weeks then once weekly for another 6 weeks.

Group Type EXPERIMENTAL

Acupuncture

Intervention Type DEVICE

Patients with stiffness of joint receive acupuncture therapy twice weekly for 6 weeks and then once weekly for 6 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Acupuncture

Patients with stiffness of joint receive acupuncture therapy twice weekly for 6 weeks and then once weekly for 6 weeks.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. History of stage I-III breast cancer and free of disease by clinical examination
2. Postmenopausal or premenopausal with ovarian suppression
3. Currently receiving aromatase inhibitors (Anastrozole, Letrozole, or Exemestane) treatment
4. With joint stiffness attributed to the use of aromatase inhibitors
5. Having had joint stiffness for at least 1 months
6. Having had at least 15 days with stiffness in the preceding 30 days

Exclusion Criteria

1. Women with recurrent or metastatic breast cancer
2. Women having finished chemotherapy or radiation therapy less than 1 months prior to enrollment
3. Women with history of bleeding disorder
4. Women with joint stiffness attributed to inflammatory arthritis, such as rheumatoid arthritis, spondy loarthritis and osteoarthritis
5. Women having joint stiffness prior to AI treatment
6. Women that have received treatment of any kind for joint stiffness within the last 3 months
7. Women that have previously received the acupuncture treatment before for any reason
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Affiliated Hospital of Qinghai University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jiuda Zhao

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jiuda Zhao

Role: PRINCIPAL_INVESTIGATOR

the Affiliated Hospital of Qinghai University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Affiliated Hospital of Qinghai University, Affiliated Cancer Hospital of Qinghai University

Xining, Qinghai, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Dengfeng Ren

Role: CONTACT

Phone: +8613086297659

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Dengfeng Ren

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AHQU-2021004

Identifier Type: -

Identifier Source: org_study_id